Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Pataje G. Prasanna; Gayle E. Woloschak; Andrea L. DiCarlo; Jeffrey C. Buchsbaum; Dörthe Schaue; Arnab Chakravarti; Francis A. Cucinotta; Silvia C. Formenti; Chandan Guha; Dale J. Hu; Mohammad K. Khan; David G. Kirsch; Sunil Krishnan; Wolfgang W. Leitner; Brian Marples; William McBride; Minesh P. Mehta; Shahin Rafii; Elad Sharon; Julie M. Sullivan; Ralph R. Weichselbaum; Mansoor M. Ahmed; Bhadrasain Vikram; C. Norman Coleman; Kathryn D. Held

doi:10.1667/RADE-20-00211.1

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. SullivanRalph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.

Original language	English (US)
Pages (from-to)	452-464
Number of pages	13
Journal	Radiation Research
Volume	194
Issue number	5
DOIs	https://doi.org/10.1667/RADE-20-00211.1
State	Published - Nov 2020

ASJC Scopus subject areas

Radiation
Biophysics
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1667/RADE-20-00211.1

Cite this

Prasanna, P. G., Woloschak, G. E., DiCarlo, A. L., Buchsbaum, J. C., Schaue, D., Chakravarti, A., Cucinotta, F. A., Formenti, S. C., Guha, C., Hu, D. J., Khan, M. K., Kirsch, D. G., Krishnan, S., Leitner, W. W., Marples, B., McBride, W., Mehta, M. P., Rafii, S., Sharon, E., ... Held, K. D. (2020). Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiation Research, 194(5), 452-464. https://doi.org/10.1667/RADE-20-00211.1

Prasanna, PG, Woloschak, GE, DiCarlo, AL, Buchsbaum, JC, Schaue, D, Chakravarti, A, Cucinotta, FA, Formenti, SC, Guha, C, Hu, DJ, Khan, MK, Kirsch, DG, Krishnan, S, Leitner, WW, Marples, B, McBride, W, Mehta, MP, Rafii, S, Sharon, E, Sullivan, JM, Weichselbaum, RR, Ahmed, MM, Vikram, B, Norman Coleman, C & Held, KD 2020, 'Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?', Radiation Research, vol. 194, no. 5, pp. 452-464. https://doi.org/10.1667/RADE-20-00211.1

@article{6a929bd85d244630bf84645749f01dad,

title = "Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?",

abstract = "The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.",

author = "Prasanna, {Pataje G.} and Woloschak, {Gayle E.} and DiCarlo, {Andrea L.} and Buchsbaum, {Jeffrey C.} and D{\"o}rthe Schaue and Arnab Chakravarti and Cucinotta, {Francis A.} and Formenti, {Silvia C.} and Chandan Guha and Hu, {Dale J.} and Khan, {Mohammad K.} and Kirsch, {David G.} and Sunil Krishnan and Leitner, {Wolfgang W.} and Brian Marples and William McBride and Mehta, {Minesh P.} and Shahin Rafii and Elad Sharon and Sullivan, {Julie M.} and Weichselbaum, {Ralph R.} and Ahmed, {Mansoor M.} and Bhadrasain Vikram and {Norman Coleman}, C. and Held, {Kathryn D.}",

note = "Publisher Copyright: {\'O}2020 by Radiation Research Society.",

year = "2020",

month = nov,

doi = "10.1667/RADE-20-00211.1",

language = "English (US)",

volume = "194",

pages = "452--464",

journal = "Radiation Research",

issn = "0033-7587",

publisher = "Radiation Research Society",

number = "5",

}

TY - JOUR

T1 - Low-Dose Radiation Therapy (LDRT) for COVID-19

T2 - Benefits or Risks?

AU - Prasanna, Pataje G.

AU - Woloschak, Gayle E.

AU - DiCarlo, Andrea L.

AU - Buchsbaum, Jeffrey C.

AU - Schaue, Dörthe

AU - Chakravarti, Arnab

AU - Cucinotta, Francis A.

AU - Formenti, Silvia C.

AU - Guha, Chandan

AU - Hu, Dale J.

AU - Khan, Mohammad K.

AU - Kirsch, David G.

AU - Krishnan, Sunil

AU - Leitner, Wolfgang W.

AU - Marples, Brian

AU - McBride, William

AU - Mehta, Minesh P.

AU - Rafii, Shahin

AU - Sharon, Elad

AU - Sullivan, Julie M.

AU - Weichselbaum, Ralph R.

AU - Ahmed, Mansoor M.

AU - Vikram, Bhadrasain

AU - Norman Coleman, C.

AU - Held, Kathryn D.

PY - 2020/11

Y1 - 2020/11

N2 - The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.

AB - The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85096152442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096152442&partnerID=8YFLogxK

U2 - 10.1667/RADE-20-00211.1

DO - 10.1667/RADE-20-00211.1

M3 - Review article

C2 - 33045077

AN - SCOPUS:85096152442

SN - 0033-7587

VL - 194

SP - 452

EP - 464

JO - Radiation Research

JF - Radiation Research

IS - 5

ER -

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this